Cordasco Financial Network’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$42K Hold
572
0.03% 212
2022
Q1
$51K Buy
572
+72
+14% +$6.65K 0.03% 193
2021
Q4
$56K Hold
500
0.04% 185
2021
Q3
$63K Hold
500
0.04% 163
2021
Q2
$68K Hold
500
0.05% 156
2021
Q1
$68K Buy
+500
New +$74.9K 0.05% 145
2020
Q4
Sell
-500
Closed -$56K 553
2020
Q3
$56K Hold
500
0.05% 150
2020
Q2
$56K Hold
500
0.05% 140
2020
Q1
$39K Hold
500
0.04% 145
2019
Q4
$48K Hold
500
0.04% 142
2019
Q3
$38K Hold
500
0.04% 167
2019
Q2
$44K Hold
500
0.04% 144
2019
Q1
$45K Hold
500
0.05% 147
2018
Q4
$36K Hold
500
0.04% 156
2018
Q3
$48K Hold
500
0.05% 134
2018
Q2
$48K Hold
500
0.05% 133
2018
Q1
$44K Buy
+500
New +$45.6K 0.05% 129

Other funds holding XBI

Cordasco Financial Network's XBI Position: Q2 2022 in Review

Cordasco Financial Network held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2022 at 572 shares worth $42K. The position accounts for 0.03% of the portfolio, ranked #212.

Cordasco Financial Network first reported a position in XBI in Q1 2018 and has held it in 17 quarters since. The position peaked at $68K in Q2 2021. 706 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

  • Cordasco Financial Network held 572 shares of State Street SPDR S&P Biotech ETF worth $42K as of Q2 2022.
  • Cordasco Financial Network left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2022.
  • State Street SPDR S&P Biotech ETF made up 0.03% of Cordasco Financial Network's portfolio in Q2 2022, its #212 holding.
  • Cordasco Financial Network first reported a position in State Street SPDR S&P Biotech ETF in Q1 2018 and has held it in 17 quarters since.
  • Cordasco Financial Network's State Street SPDR S&P Biotech ETF position peaked at $68K in Q2 2021.
  • 706 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on Cordasco Financial Network's 13F filing for Q2 2022, filed 15 Jul 2022.